Lawrence Otto Klein - 16 Aug 2022 Form 4 Insider Report for CRISPR Therapeutics AG (CRSP)

Reporting relationship
CBO & COO
Issuer ticker
CRSP
Reported as of
16 Aug 2022
Net transaction value
$0
Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
4
Accepted by SEC
18 Aug 2022, 17:36:02 UTC
Prior SEC filing
06 Jul 2022
Next SEC filing
13 Oct 2022
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Elizabeth Ryland Waldinger, attorney-in-fact

Key filing fact

Lawrence Otto Klein filed Form 4 for CRISPR Therapeutics AG (CRSP) on 18 Aug 2022.

Key facts

  • This page summarizes Lawrence Otto Klein's Form 4 filing for CRISPR Therapeutics AG (CRSP).
  • 1 reported transaction and 1 derivative row are listed below.
  • Accepted by SEC: 18 Aug 2022, 17:36.

Change

  • Previous filing in this sequence was filed on 06 Jul 2022.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CRSP transaction Derivative

Restricted Stock Units

Award

Transaction value
$0
Shares
+12,500
Change %
Price
$0.000000
Shares after
12,500
Date
16 Aug 2022
Ownership
Direct
Underlying class
Common Shares
Underlying amount
12,500
Exercise price
Footnotes
F1, F2
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.

Footnote F2

The restricted stock units shall vest in full on August 16, 2023, subject to continued service to the Company or any of its subsidiaries.

SEC remarks

Exhibit 24 - Power of Attorney

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .